{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:59:31Z","timestamp":1792454371312,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by the loss of motor neurons in the spinal cord. Our team has initiated clinical trials using adeno-associated virus serotype 9 (AAV9) vectors carrying a codon-optimized\u00a0human SMN1 (coSMN1) gene, delivered via intrathecal (IT) injection. Here, we present the preclinical research that laid the groundwork for these trials, offering comprehensive data on the efficacy and safety of AAV9-coSMN1 in both murine models and non-human primates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and method<\/jats:title>\n                    <jats:p>\n                      We developed a codon-optimized\n                      <jats:italic>h<\/jats:italic>\n                      <jats:italic>SMN1<\/jats:italic>\n                      expression cassette and analyzed SMN protein levels using Western blot and immunofluorescence. Taiwanese SMA-like mouse model was employed to assess tail length preservation, as well as to examine motor neuron and skeletal muscle pathological phenotypes through immunofluorescence and histopathological staining. Serum biomarkers in both mice and cynomolgus monkeys were measured using a blood chemistry analyzer. The in-vivo biodistribution of AAV9-coSMN1 and toxicological profile were investigated through quantitative Polymerase Chain Reaction(qPCR) and histopathological staining.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Codon optimization of\n                      <jats:italic>h<\/jats:italic>\n                      <jats:italic>SMN1<\/jats:italic>\n                      led to enhanced gene expression and increased SMN protein levels in vitro. AAV9-coSMN1 demonstrated significant therapeutic efficacy in a Type 3 SMA mouse model, effectively rescuing motor neurons, preserving tail integrity, and improving skeletal muscle histopathology. In vivo studies, both mice and cynomolgus monkeys revealed widespread CNS distribution following a single intracerebroventricular or intrathecal injection, with no observed toxic inflammatory responses in the dorsal root ganglia. Peripheral organs also showed detectable levels of the vector gene, indicating effective systemic distribution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The preclinical evaluation confirms that AAV9-coSMN1 is a safe and effective therapeutic candidate for SMA, with potential applicability across various phenotypes. The study provides critical data supporting its advancement to clinical trials, underscoring its promise for broader neurological applications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-025-01207-4","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T14:22:57Z","timestamp":1745936577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical evaluation of AAV9-coSMN1 gene therapy for spinal muscular atrophy: efficacy and safety in mouse models and non-human primates"],"prefix":"10.1186","volume":"31","author":[{"given":"Wenhao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"1","key":"1207_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12038-023-00412-9","volume":"49","author":"A Aasdev","year":"2024","unstructured":"Aasdev A, Sreelekshmi RS, Iyer VR, et al. Spinal muscular atrophy: Molecular mechanism of pathogenesis, diagnosis, therapeutics, and clinical trials in the Indian context. J Biosci. 2024;49(1):36.","journal-title":"J Biosci"},{"issue":"3","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74(3):560\u20136.","journal-title":"J Hepatol"},{"key":"1207_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41434-021-00292-4","volume":"9","author":"EM Chilcott","year":"2022","unstructured":"Chilcott EM, et al. Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models. Gene Ther. 2022;9:498\u2013512.","journal-title":"Gene Ther"},{"issue":"2","key":"1207_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00019052-199904000-00002","volume":"12","author":"NH Gendron","year":"1999","unstructured":"Gendron NH, MacKenzie AE. Spinal muscular atrophy: molecular pathophysiology. Curr Opin Neurol. 1999;12(2):137\u201342.","journal-title":"Curr Opin Neurol"},{"key":"1207_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","volume":"10","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux J, Hinderer C, Goode T, et al. Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques. Mol Therapy Methods Clin Dev. 2018;10:79\u201388.","journal-title":"Mol Therapy Methods Clin Dev"},{"issue":"569","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"9188","DOI":"10.1126\/scitranslmed.aba9188","volume":"12","author":"J Hordeaux","year":"2020","unstructured":"Hordeaux J, Buza EL, Jeffrey B, et al. MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci Trans Med. 2020;12(569):9188.","journal-title":"Sci Trans Med"},{"key":"1207_CR7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","volume":"35","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs. 2021;35:1317\u201328.","journal-title":"CNS Drugs"},{"issue":"1","key":"1207_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","volume":"24","author":"HM Hsieh-Li","year":"2000","unstructured":"Hsieh-Li HM, Chang JG, Jong YJ, et al. A mouse model for spinal muscular atrophy. Nat Genet. 2000;24(1):66\u201370.","journal-title":"Nat Genet"},{"issue":"3","key":"1207_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"M Kathrin","year":"2015","unstructured":"Kathrin M, Laura F, Leah S, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose\u2013response study in mice and nonhuman primates. Mol Ther. 2015;23(3):477\u201387.","journal-title":"Mol Ther"},{"key":"1207_CR10","first-page":"51863","volume":"91","author":"JY Kim","year":"2014","unstructured":"Kim JY, Grunke SD, Levites Y, et al. Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. J Visual Exp: Jove. 2014;91:51863.","journal-title":"J Visual Exp: Jove"},{"issue":"4","key":"1207_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/088307389100600408","volume":"6","author":"DW Kingma","year":"1991","unstructured":"Kingma DW, Feeback DL, Marks WA, et al. Selective type II muscle fiber hypertrophy in severe infantile spinal muscular atrophy. J Child Neurol. 1991;6(4):329\u201334.","journal-title":"J Child Neurol"},{"issue":"9\u201310","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/hum.2024.022","volume":"35","author":"C Lin","year":"2024","unstructured":"Lin C, Greenblatt MB, Gao G, et al. Development of AAV-mediated gene therapy approaches to treat skeletal diseases. Hum Gene Ther. 2024;35(9\u201310):317\u201328.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"1207_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ymthe.2023.11.022","volume":"32","author":"S Liu","year":"2024","unstructured":"Liu S, Li J, Peraramelli S, et al. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Mol Ther. 2024;32(1):74\u201383.","journal-title":"Mol Ther"},{"issue":"16","key":"1207_CR14","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1097\/CM9.0000000000003210","volume":"137","author":"X Ma","year":"2024","unstructured":"Ma X, Zhuang L, Ma W, et al. Treatment of SMA type 1 infants using a single-dose AAV9-mediated gene therapy via intrathecal injection of GC101: An open-label, single-arm study. Chin Med J. 2024;137(16):1976\u20138.","journal-title":"Chin Med J"},{"issue":"18","key":"1207_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"7","key":"1207_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"key":"1207_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Pera MC, Scoto M, et al. Spinal muscular atrophy \u2014 insights and challenges in the treatment era. Nat Rev Neurol. 2020;16:706\u201315.","journal-title":"Nat Rev Neurol"},{"key":"1207_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, et al. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8:52.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1207_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"K Meyer","year":"2015","unstructured":"Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther. 2015;23(3):477\u201387.","journal-title":"Mol Ther"},{"issue":"12","key":"1207_CR20","first-page":"E2347","volume":"114","author":"J Mohini","year":"2017","unstructured":"Mohini J, Christina F, Patrick C, et al. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage. PNAS. 2017;114(12):E2347\u201356.","journal-title":"PNAS"},{"key":"1207_CR21","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1007\/s00415-023-11658-6","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N, et al. Correction to: two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neuro. 2023;270:2547\u20139.","journal-title":"J Neuro"},{"key":"1207_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","volume":"36","author":"J Paik","year":"2022","unstructured":"Paik J. Risdiplam: a review in spinal muscular atrophy. CNS Drugs. 2022;36:401\u201310.","journal-title":"CNS Drugs"},{"issue":"6","key":"1207_CR23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaneurol.2015.0178","volume":"72","author":"M Ripolone","year":"2015","unstructured":"Ripolone M, Ronchi D, Violano R, et al. Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol. 2015;72(6):666\u201375.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1207_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/ph17030394","volume":"17","author":"R Ruggiero","year":"2024","unstructured":"Ruggiero R, Balzano N, Nicoletti MM, et al. Real-world safety data of the orphan drug onasemnogene abeparvovec (Zolgensma\u00ae) for the SMA rare disease: a pharmacovigilance study based on the EMA adverse event reporting system. Pharmaceuticals. 2024;17(3):394.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1207_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, et al. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9(1):78.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"1207_CR26","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1093\/hmg\/ddq340","volume":"19","author":"TM Wishart","year":"2010","unstructured":"Wishart TM, Huang JPW, Murray LM, et al. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet. 2010;19(21):4216\u201328.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1207_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/088307389100600407","volume":"6","author":"EL Zalneraitis","year":"1991","unstructured":"Zalneraitis EL, Halperin JJ, Grunnet ML, et al. Muscle biopsy and the clinical course of infantile spinal muscular atrophy. J Child Neurol. 1991;6(4):324\u20138.","journal-title":"J Child Neurol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01207-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01207-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01207-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T14:22:58Z","timestamp":1745936578000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01207-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01207-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5051200\/v1","asserted-by":"object"}]},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Lab animal Ethics Committee of the GeneCradle Therapeutics Inc. (Beijing). The GLP animal studies (ACU21-1273 and IACUC-SN20274-XJ) were approved from the Animal Ethics Committee of the GLP research institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}